STOCK TITAN

Ardelyx SEC Filings

ARDX NASDAQ

Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Explore Ardelyx's groundbreaking work in renal disease and gastrointestinal therapies through AI-decoded SEC filings. Stock Titan's platform transforms complex clinical trial data from 10-K reports into clear insights about tenapanor's progress in treating hyperphosphatemia and IBS-C. Track real-time Form 4 filings to monitor executive transactions tied to drug development milestones, while our AI highlights partnership impacts in quarterly 10-Q filings with Japanese and Chinese collaborators.

Understand how Ardelyx's 10-K disclosures reveal clinical trial outcomes for their NHE3 inhibitor platform, while 10-Q filings detail R&D investments in first-in-class therapies. Get alerts for material events like FDA communications through 8-K filings, and analyze proxy statements for executive compensation linked to pipeline success. Our platform deciphers biotech-specific disclosures about phase 3 trial results and global commercialization strategies.

Stock Titan simplifies Ardelyx's regulatory narrative with AI-powered explanations of drug approval timelines in annual reports and real-time tracking of insider transactions affecting stock volatility. Access expert analyses connecting financial disclosures to therapeutic pipeline progress, including royalty agreements with international partners revealed in quarterly filings. Stay ahead with plain-English breakdowns of complex biopharma accounting in every filing type.

Filing
Rhea-AI Summary

Millennium Management LLC, along with affiliated entities, has reported acquiring a significant stake in Ardelyx. According to the Schedule 13G filing dated June 28, 2025, the reporting persons collectively own 12,099,947 shares, representing a 5.1% ownership in the company.

The reporting persons include:

  • Millennium Management LLC (Delaware)
  • Millennium Group Management LLC (Delaware)
  • Israel A. Englander (United States)

All three parties share voting and dispositive power over the reported shares, with no sole voting or dispositive power. The securities were not acquired for the purpose of changing or influencing control of Ardelyx. The shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Mr. Englander.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Ardelyx Director Robert B. Bazemore reported two significant equity transactions on June 18, 2025:

  • Acquired 41,551 Restricted Stock Units (RSUs) at $0, convertible to common stock on a 1:1 basis upon vesting. These RSUs were granted under the company's Non-Employee Director Compensation Program.
  • Received a stock option grant for 54,059 shares with an exercise price of $3.61 per share, expiring June 18, 2035. The option vests monthly at 1/12th of shares, with potential accelerated vesting at the next annual stockholder meeting.

Following these transactions, Bazemore directly owns 41,551 shares of common stock (through RSUs) and options for 54,059 shares. These grants represent standard non-employee director compensation and align the director's interests with shareholders through equity-based compensation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Ardelyx, Inc. (ARDX) – Form 4 insider transaction filed 06/23/2025

Board member Richard J. Rodgers reported routine, compensation-related equity grants dated 06/18/2025 under Ardelyx’s Non-Employee Director Compensation Program:

  • 21,468 common shares issued in lieu of cash fees, increasing his direct holdings to 371,992 shares.
  • 41,551 restricted stock units (RSUs); each RSU converts 1-for-1 to common stock as it vests, bringing total directly held shares to 413,543 on a fully delivered basis.
  • 54,059 stock options with a $3.61 exercise price, 10-year term (expiring 06/18/2035). Vesting is 1/12 monthly with full acceleration at the next annual meeting if service continues.

No sales were reported and all awards were granted at $0 cost to the director. Transactions reflect standard annual director compensation and represent a small, immaterial dilution to existing shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

On 18 June 2025, Ardelyx, Inc. (ARDX) filed a Form 4 disclosing that director Merdad Parsey received 15,235 shares of the company’s common stock. The shares were issued at a price of $0 under the company’s Non-Employee Director Compensation Program, reflecting the director’s election to take equity instead of cash fees. Following the transaction, Parsey’s direct beneficial ownership stands at 57,291 shares. No sales, dispositions, or derivative security activities were reported, and the filing contains no additional financial metrics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Director David M. Mott of Ardelyx reported multiple equity transactions on June 18, 2025:

  • Acquired 31,163 shares of common stock at $0 through the Non-Employee Director Compensation Program (elected stock instead of cash)
  • Received 41,551 Restricted Stock Units (RSUs) under the same program
  • Granted stock options to purchase 54,059 shares at $3.61 per share, expiring June 18, 2035

Following these transactions, Mott directly owns 2,969,585 shares, including 87,566 shares held for entities associated with New Enterprise Associates. The stock options vest monthly at 1/12th of shares, with full acceleration at the next annual stockholder meeting. The RSUs convert 1:1 to common stock upon vesting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Ardelyx Director Onaiza Cadoret-Manier received new equity compensation grants on June 18, 2025, as part of the company's Non-Employee Director Compensation Program. The transactions include:

  • 41,551 Restricted Stock Units (RSUs) acquired at $0, bringing total direct ownership to 151,701 shares
  • 54,059 Stock Options granted with an exercise price of $3.61, expiring June 18, 2035

The stock options vest monthly at 1/12th of shares, with accelerated vesting at the next annual stockholder meeting for any unvested portions. The RSUs convert to common stock on a 1:1 basis upon vesting. These grants represent standard non-employee director compensation rather than open market transactions, indicating continued board service commitment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Ardelyx Director Muna Bhanji reported two equity compensation grants on June 18, 2025:

  • 41,551 Restricted Stock Units (RSUs) awarded at $0, bringing total direct common stock ownership to 137,353 shares
  • 54,059 Stock Options granted with a strike price of $3.61, exercisable until June 18, 2035

The equity awards were issued under Ardelyx's Non-Employee Director Compensation Program. The stock options vest monthly at 1/12th of shares, with accelerated vesting at the next annual stockholder meeting if unvested portions remain. The RSUs convert 1:1 to common stock upon vesting. This Form 4 filing indicates standard board compensation rather than open market transactions, reflecting ongoing director compensation arrangements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Ardelyx Director William C. Bertrand Jr. reported multiple equity transactions on June 18, 2025, significantly increasing his beneficial ownership position:

  • Acquired 19,390 shares of common stock at $0 through the Non-Employee Director Compensation Program, choosing stock instead of cash compensation
  • Received 41,551 Restricted Stock Units (RSUs) under the same program, convertible 1:1 into common shares upon vesting
  • Granted stock options to purchase 54,059 shares at $3.61 per share, expiring June 18, 2035. Options vest monthly at 1/12th rate with potential acceleration at next annual stockholder meeting

Following these transactions, Bertrand directly owns 290,707 shares of common stock and 54,059 stock options. These grants reflect standard non-employee director compensation rather than open market transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Ardelyx Director David M. Mott has increased his position in the company through a significant stock purchase on June 16, 2025. Mott acquired 200,000 shares of common stock at a weighted average price of $3.6294 per share, with individual trade prices ranging from $3.57 to $3.70.

Following this transaction, Mott's total beneficial ownership stands at 2,896,871 shares held directly. Of this total, 87,566 shares are held for the benefit of entities associated with New Enterprise Associates, for which Mott disclaims beneficial ownership except for his pecuniary interest.

This insider purchase by a director signals potential confidence in the company's prospects. The transaction was reported via Form 4 filing, executed through multiple trades, and was filed within the required reporting period. The filing was completed through an attorney-in-fact on June 19, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Filing
Rhea-AI Summary

Ardelyx held its 2025 Annual Meeting of Stockholders on June 18, 2025, where shareholders voted on four key proposals. 187,162,927 shares out of 239,255,212 outstanding shares were represented at the meeting.

Key outcomes include:

  • Board Elections: Class II directors David Mott and Michael Raab were elected to serve until 2028, with Raab receiving stronger shareholder support (101.2M vs 93M votes)
  • Say-on-Pay: Approved with strong support (131.3M votes in favor)
  • Auditor Ratification: Ernst & Young LLP confirmed as independent auditor with overwhelming approval (182.5M votes in favor)
  • Equity Plan Amendment: The amendment to the Amended and Restated 2014 Equity Incentive Award Plan passed with moderate support (85M votes for vs 57.4M against)

The meeting demonstrated generally positive shareholder sentiment, though the Equity Plan Amendment faced notable opposition with approximately 40% of voting shares against the proposal.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Ardelyx (ARDX)?

The current stock price of Ardelyx (ARDX) is $3.69 as of June 28, 2025.

What is the market cap of Ardelyx (ARDX)?

The market cap of Ardelyx (ARDX) is approximately 851.7M.

What is the primary focus of Ardelyx Inc.?

Ardelyx focuses on the discovery, development, and commercialization of innovative, first-in-class medicines primarily addressing renal diseases and gastrointestinal disorders.

What are the key therapeutic areas explored by Ardelyx?

The company primarily targets treatments for conditions such as hyperphosphatemia in dialysis patients, irritable bowel syndrome with constipation (IBS-C), and potential therapies for hyperkalemia.

How does Ardelyx generate revenue?

Revenue is generated through the commercialization of its approved products in the United States and through milestone payments and royalty agreements with its international partners.

What distinguishes Ardelyx's drug development approach?

Ardelyx uses a proprietary drug discovery and design platform that focuses on innovative mechanisms of action, enabling the development of therapies that target underlying disease processes effectively.

How does the company support its global operations?

Through strategic collaborations with key international partners in markets like Japan, China, and Canada, Ardelyx leverages local expertise to navigate regulatory environments and expand patient access.

What clinical evidence supports Ardelyx's products?

Ardelyx has completed extensive phase 3 trials for its lead candidate tenapanor, generating robust data on the safety and efficacy of its treatments across multiple conditions, which reinforces its clinical credibility.

How does Ardelyx position itself in a competitive market?

By emphasizing its first-in-class therapeutic approach, robust clinical research, and strategic global partnerships, Ardelyx differentiates itself from competitors and demonstrates high levels of expertise and operational excellence.

What is the significance of Ardelyx's strategic partnerships?

These partnerships are crucial for accelerating market access, navigating regional regulatory challenges, and enhancing the overall reach of its innovative therapies, thereby supporting sustainable growth.
Ardelyx

NASDAQ:ARDX

ARDX Rankings

ARDX Stock Data

851.75M
232.89M
2.17%
64.47%
12.51%
Biotechnology
Pharmaceutical Preparations
Link
United States
FREMONT